BIIB34:BVMF
Biogen
230,10Â BRL
0,00%
(0,00) 1Â D
4. nov., 15:38:07 GMT-3 · BRL
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for BIIB34 …
Markedsverdi
37,46Â mrd.
Snittvolum
9,00
Volum
0,00
52 u høy
230,10Â BRL
52Â u lav
145,65Â BRL
Utestående aksjer
147,82Â mill.
Antall ansatte
8k
Markedsverdi
37,46Â mrd.
Snittvolum
9,00
Volum
0,00
52 u høy
230,10Â BRL
52Â u lav
145,65Â BRL
Utestående aksjer
147,82Â mill.
Antall ansatte
8k
Nyhetssaker
Fra nettkilder og nyhetspartnere
MarketWatch
·
for 3 døgn siden
Biogen Inc. stock underperforms Thursday when compared to competitors
Stocks Down Under
·
for 3 døgn siden
Biogen (NYSE:BIIB) Share Price, Forecast & Analysis
Profil
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Om Biogen
Administrerende direktørChristopher A. Viehbacher
Ansatte7,5k
Grunnlagt1978
HovedkontorCambridge, Massachusetts, USA
SektorHealth Care
Bransje-
Nettstedbiogen.com